Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Adalimumab drug presentation


Published on


Published in: Education
  • Be the first to comment

  • Be the first to like this

Adalimumab drug presentation

  2. 2. Introduction • human monoclonal antibody against TNF-alpha • C6428H9912N1694O1987S46 • organic chemical • produced by recombinant DNA technology using mammalian cell expression system • Adalimumab is used for treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease • immune system mediated diseases
  3. 3. History • 1993 - BASF bioresearch and Cambridge Antibody • 3rd TNF inhibitor approved in United States • fully human monoclonal • initially discovered using CAT’s phage display technology and being named as D2E7 • BASF bioresearch Corporation – create • Abbott Laboratories – further manufacturing and marketing
  4. 4. • 2008 - Food and Drug Administration (FDA) approved adalimumab as treatment of arthritis and Crohn’s disease • 2012 - FDA approved for treatment of ulcerative colitis • 2014 - generic drugs of adalimumab has been launched by other companies
  5. 5. • sold under the trade name, Humira • rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease • tumor necrosis factor-alpha (TNF- α) blocker
  6. 6. How it works? • directly binding to TNF- α molecules in the blood and diseased tissue • blocks its interaction with the p55 and p75 cell surface TNF receptors • lyses surface TNF expressing cells in vitro • does not bind or inactivate lymphotoxin (TNF-beta) • Excess production of TNF-alpha - rapid growth of skin cells and damages to joint tissue • Adalimumab helps to stop the inflammatory cycle of psoriatic disease and prevent from causing the inflammation that result in psoriasis plaques.
  7. 7. Prescription, Pharmacodynamics, Pharmacokinetics • prescribed by either itself or in combination with methotrexate • given after other medications has failed in treatment • safe to take it with topical treatments or pain relievers • Adult – decrease acute inflammation, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and serum cytokines (IL-6) • maximized with the maximum serum concentration • Tmax were 4.7 ± 1.6 µg/mL and 131 ± 56 hours • linear over the dose range of 0.5 to 10.0 mg/kg following a single intravenous dose
  8. 8. efficacy of adalimumab • phase II randomized placebo-controlled trial evaluate 147 patients with psoriasis that at least 5% of their (BSA) infected and minimum 10 (PASI) • Patient had achieved the primary endpoint of PASI 75 or better as compared to 4% of the patients who received placebo. • phase II trial is to compare the efficacy of adalimumab to methotrexate (MTX) and placebo.
  9. 9. • phase III trials were performed to directly compare the therapeutic efficacy, safety and tolerability and to provide greater body of data • 80patients given adalimumab, 36% patients given methotrexate and 19% patients given placebo achieving a PASI 75 response rate at a given time • (PGA) score :73% in adalimumab, 30% in methotrexate and 11% in placebo • second phase III trials was to examine the short- and long-term efficacy of adalimumab as monotherapy against placebo • treatment with 40mg adalimumab every other week • efficacy of adalimumab is sustainable.
  10. 10. • high dose in phase II - Adverse reaction of pain with injection • headache, nausea, elevated triglycerides, cough, sinus congestion, and fatigue • no increase of serious adverse events in phase III trials • recommended dose of 40 mg every other week, and the higher dose of 40 mg weekly, either alone or in combination with methotrexate or other DMARDs • short- and long-term safety, tolerability and substantial efficacy
  11. 11. Risk • developing severe and even fatal infections • Tuberculosis may be caused by a new infection or by reactivation of a previous infection • tumor necrosis factor (TNF) blocker - develop Lymphoma and other types of cancer such as hepatosplenic T-cell lymphoma (HSTCL) • attempt a TB skin test before taking Adalimumab • positive result should begin treatment for TB • negative result should also be monitored for signs of TB while using adalimumab
  12. 12. Precautions • Should not drive - dizziness or vision changes • avoid contact with people who have colds or infections • should not do any activities that may cause bruising or injury • should not breastfeed
  13. 13. Side Effects Common side effect • back pain, headache, redness or swelling at injection site • mild stomach pain, nausea or runny nose Severe side effect • rash, itching, difficulty in breathing, swelling of lips or tongue, blood in urine, burning, numbness, chest pain, fainting, blistered, peeling skin, swelling of ankles, diarrhoea or vomit.
  14. 14. Overdose • still unclear • does not show toxic effects in clinical trials
  15. 15. Challenges • target specific drugs • specialized drug for individual • competition of new generic drugs • Amgen for patenting rights
  16. 16. Conclusion • fully human monoclonal anti-TNF antibody drug • treat inflammation and chronic skin condition • Efficacy of adalimumab is sustainable • side effect isn’t life threatening • No high toxic effect • taken by itself of accompanied by some other drug